** Shares of drug developer CervoMed CRVO.O rise 58.7% to $14.25 premarket
** Co says its experimental drug, neflamapimod, significantly slowed disease progression in patients with dementia with Lewy bodies, the second most common form of dementia, based on 32-week extension data from its mid-stage trial
** The extension data come after a setback last December, when the drug failed to meet primary and secondary goals in the same trial, dragging its shares by 79%
** Patients who took neflamapimod showed a 54% lower risk of their disease getting worse compared to those who did not take the drug, co says
** Neflamapimod also reduced blood markers that indicate brain cell damage
** CRVO plans to meet with FDA in Q4 2025 to discuss late-stage trials
** As of last close, stock
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.